Prophylactic Eculizumab after Renal Transplantation in Atypical Hemolytic–Uremic Syndrome

To the Editor: Atypical hemolytic–uremic syndrome is a rare microangiopathic hemolytic condition characterized by thrombocytopenia and acute renal failure.1 The prognosis for patients with atypical hemolytic–uremic syndrome with a factor H mutation is poor; 60% have end-stage renal disease or die within a year.2 The expected rate of graft failure due to recurrent atypical hemolytic–uremic syndrome among patients with a factor H or factor I mutation is 80% within 1 to 2 years.3 Here, we describe a child with atypical hemolytic–uremic syndrome and a known factor H mutation who had normal renal function 1 year after high-risk kidney transplantation with . . .